721 - 730 of 7915 Results
Title
Year
-
OPENTitle: LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent mannerJournal Name: Cell Death & DiseasePublisher: Springer Science and Business Media LLCVol: 14Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41419-023-05964-0Best OA location URL: https://www.nature.com/articles/s41419-023-05964-0.pdfCitation Count: 6
-
OPENTitle: Longitudinal in vivo metabolic labeling reveals tissue-specific mitochondrial proteome turnover rates and proteins selectively altered by parkin deficiencyJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-023-38484-0Best OA location URL: https://www.nature.com/articles/s41598-023-38484-0.pdfCitation Count: 3
-
OPENTitle: MAPT allele and haplotype frequencies in Nigerian Africans: Population distribution and association with Parkinson's disease risk and age at onsetJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 113Issue #:Start Page: 105517End Page: 105517Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105517Best OA location URL: https://doi.org/10.1101/2023.03.24.23287684Citation Count: 3
-
OPENTitle: Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease ProgressionJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 13Issue #: 6Start Page: 899End Page: 916Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-223433Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223433?id=journal-of-parkinsons-disease%2Fjpd223433Citation Count: 7
-
OPENTitle: Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s diseaseJournal Name: Neurological SciencesPublisher: Springer Science and Business Media LLCVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s10072-023-06956-wBest OA location URL: https://link.springer.com/content/pdf/10.1007/s10072-023-06956-w.pdfCitation Count: 4
-
RESTRICTEDTitle: PTPA variants are rare in early-onset and familial Parkinson’s diseaseJournal Name: BrainPublisher: Oxford University Press (OUP)Vol: 146Issue #: 12Start Page: e125End Page: e127Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1093/brain/awad244Citation Count: 1
-
OPENTitle: Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neuronsJournal Name: Nature NeurosciencePublisher: Springer Science and Business Media LLCVol: 26Issue #: 8Start Page: 1417End Page: 1428Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41593-023-01390-9Citation Count: 32
-
OPENTitle: Cerebral chemoarchitecture shares organizational traits with brain structure and functionJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 12Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.7554/elife.83843Best OA location URL: https://doi.org/10.7554/elife.83843Citation Count: 7
-
RESTRICTEDTitle: Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-023-00535-8Best OA location URL: https://www.nature.com/articles/s41531-023-00535-8.pdfCitation Count: 9
-
RESTRICTEDTitle: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trialJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 114Issue #:Start Page: 105511End Page: 105511Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511Citation Count: 2